Cellectis, a clinical-stage biotechnology company specializing in gene-editing for cell and gene therapies, will release its financial results for Q2 2026 on August 6, 2026. The results will be available on their website, but no conference call will be held for discussion. Cellectis focuses on developing off-the-shelf CAR T immunotherapies and has in-house manufacturing capabilities, positioning itself as a key player in the gene editing industry. The company is headquartered in Paris and operates in New York and Raleigh.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.globenewswire.com/news-release/2026/07/30/3336464/0/en/cellectis-to-report-second-quarter-financial-results-on-august-6-2026.html
